ASH 2023: The Most Relevant Multiple Myeloma Data Presented
Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.
HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC
Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.
Detailing the Impact on SOC in GI Cancer After ASCO GI
Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.
